In its notice to the Tel Aviv Stock Exchange (TASE), Brainsway stated, "This trial is part of the company's strategy to conduct human clinical trials to test the effectiveness of the device for the treatment of a range of illnesses, in addition to depression and including Alzheimer's, and Parkinson's, and the treatment cannabis and cocaine addiction."
Brainsway is already conducting a number of clinical trials to test the effectiveness of Deep TMS. In April, it announced a trial with the US National Institute of Drug Abuse for treatment of cocaine addiction. The company is also testing the device as a cure for obesity.
Brainsway's share rose 7.8% to NIS 12.20 today.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments